Navigation Links
Viveve-Sponsored Research Accepted for Presentation at Two Prestigious International Conferences
Date:7/14/2010

PALO ALTO, Calif., July 14 /PRNewswire/ -- Viveve, Inc., a women's sexual health company that has developed a medical device and procedure to treat vaginal laxity, recently received notification that its sponsored abstracts were accepted for the 2010 International Meetings for the International Continence Society (ICS), International Urogynocological Association (IUGA), being held as a joint meeting in 2010, and the International Society of Sexual Medicine (ISSM). The subject of the abstracts focused on research with women and OB/GYNs regarding patients' sexual health, attitudes on vaginal laxity after childbirth, and the lack of conversation about these topics between a patient and her doctor.

"I believe the fact that these two abstracts were both accepted at such highly regarded conferences on women's health and women's sexual health demonstrate the growing interest and attention worldwide to these very important topics," said Dr. Leah Millheiser, OB/GYN and Director of the Women's Sexual Health Program at Stanford University and first author on both abstract submissions.

The abstract submitted and accepted for ICS/IUGA titled "A Cross-Sectional Survey to Assess the Prevalence and Symptoms Associated with Laxity of the Vaginal Introitus" reports on findings from qualitative and quantitative research conducted with women in the United States 25-55 years old, who have delivered at least one child vaginally. This abstract was accepted as a Podium Presentation at the Joint Meeting of ICS/IUGA which will take place in Toronto, Canada, August 23-27, 2010.

The abstract submitted and accepted for ISSM titled "Cross-Sectional Survey of Sexual Health and Vaginal Laxity Following Vaginal Delivery" reports on findings in two independent quantitative research studies, one study with 421 women in the U.S. 25-55 years old who've delivered at least one child vaginally; the other study with 524 OB/GYNs practicing in the United States. This abstract was accepted as an Unmoderated Poster Presentation at the 14th World Meeting of the ISSM, which will take place in Seoul, Korea, September 26-30, 2010.

"We are very pleased ICS, IUGA and ISSM are acknowledging the importance of this research to their memberships," says Kerry Pope, CEO of Viveve. "We will continue to share our knowledge about vaginal laxity and women's desire to communicate its impact on their sexual health to their OB/GYNs."

For more information on the ISSM meeting, please visit: http://www.issm2010.info/site/

For more information on the joint ICS/IUGA meeting, please visit: www.ics-iuga.com

To review the abstracts, please visit: http://www.viveve.com/clinical/publications/

About Viveve™

Viveve is a privately held women's sexual health company based in Palo Alto, California. The Viveve System is a medical device used for the nonsurgical procedure of post-birth laxity of the vaginal introitus, a medically recognized quality of life condition. The Viveve system received a general 510(k) clearance from FDA in 2008.

The company's Series A financing was led by GBS Venture Partners and 5AM Ventures. For more information, visit the Viveve Web site at www.viveve.com or phone 650-321-3332.


'/>"/>
SOURCE Viveve
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... "Latin America Pharmaceutical Contract Manufacturing Services Market Analysis By Service ... And Segment Forecasts, 2014 - 2025" report to their ... The Latin ... USD 21.0 billion by 2025 Low drug registration ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... release financial results for the first quarter 2017 after ... The Company,s management team will host a corresponding conference ... ET. Investors interested in listening to the ... for domestic callers or (703) 326-3030 for international callers, ...
(Date:4/19/2017)... 19, 2017 The Global Effective Microorganisms ... 2022 report has covered and analysed the potential of Global ... market size, shares and growth factors. The report identifies and ... opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Children and adolescents who ... experiences than children in the general population. That’s because foster care is designed ... family challenges. While no fault of their own, youth who have experienced trauma ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... hERG liability could substantially improve drug safety and minimize the cost of development. ... validating ion channel inhibition using cell lines and for cardiac toxicity using induced ...
(Date:4/28/2017)... ... 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, ... to and which He does not. Yisrayl says with so many titles and names ... name, but he says with a little Scripture, backed with a lot of research, the ...
(Date:4/28/2017)... ... 28, 2017 , ... Intellitec Solutions announced the publication of ... Microsoft Dynamics GP solution that integrates to their PointClickCare EHR software package. With ... care, Brooke Grove now has the capability to achieve its goal for a ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor ... leant his presence to an educational purpose as the host of the “Informed” series. ... cancer. In a recent episode, the series focuses on thyroid cancer. , Although thyroid ...
Breaking Medicine News(10 mins):